PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1808889
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1808889
Cardiovascular Information System Market size was valued at US$ 1,390.32 Million in 2024, expanding at a CAGR of 8.20% from 2025 to 2032.
The Cardiovascular Information System (CVIS) is a digital platform that collects, manages, and analyzes cardiovascular patient data to enhance clinical decision-making and workflow efficiency. Growing cardiovascular disease burden worldwide, increasing demand for integrated and cloud-based imaging solutions, and the shift toward value-based care are fueling adoption across hospitals and specialty clinics. For instance, the World Health Organization reported that cardiovascular diseases were responsible for over 20.5 million deaths globally in 2023, prompting greater investments in diagnostic and monitoring technologies. However, high installation and maintenance costs, along with interoperability challenges between legacy systems, remain key restraints. Nonetheless, the market holds strong opportunities through AI-powered analytics, EHR integration, and expanding telecardiology services in emerging economies.
Cardiovascular Information System Market- Market Dynamics
Rising Cardiac Cases and Shift Toward Integrated Care Accelerate Adoption of Cardiovascular Information Systems
The adoption of Cardiovascular Information Systems (CVIS) is accelerating as healthcare providers seek integrated platforms to manage growing cardiac caseloads and enhance care coordination. According to the World Health Organization, cardiovascular diseases accounted for approximately 20.5 million deaths in 2023, making them the leading cause of global mortality. Hospitals are increasingly adopting CVIS to streamline cath lab workflows, integrate with electronic health records (EHR), and enable remote access to imaging and reports. For instance, the U.S. Department of Veterans Affairs has implemented enterprise imaging systems across its network to support cardiology diagnostics. Such developments highlight a strong shift toward digital, data-driven, and patient-centric cardiovascular care.
Cardiovascular Information System Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 8.20% over the forecast period (2025-2032)
Based on Component segmentation, Software was predicted to show maximum market share in the year 2024
Based on System segmentation, Cardiovascular Information Systems (CVIS) was the leading System in 2024
Based on Functionality segmentation, Data Management was the leading Functionality in 2024
Based on Deployment Mode segmentation, On-premise was the leading Deployment Mode in 2024
Based on Application segmentation, Catheterization Lab CVIS Solutions was the leading Application in 2024
On the basis of region, North America was the leading revenue generator in 2024
The Global Cardiovascular Information System Market is segmented on the basis of Component, System, Functionality, Deployment Mode, Application, and Region.
The market is divided into three categories based on Component: Software, Services, and Hardware. Software holds the highest share due to its central role in data integration, imaging, and analytics. Services follow, driven by demand for implementation, maintenance, and training. Hardware ranks lower, mainly consisting of workstations and servers supporting the software infrastructure.
The market is divided into two categories based on System: Cardiovascular Information Systems (CVIS) and Cardiology Picture Archiving and Communication Systems (CPACS). Cardiovascular Information Systems (CVIS) hold a larger market share due to their comprehensive capabilities in data management, reporting, and workflow optimization. However, Cardiology Picture Archiving and Communication Systems (CPACS) continue to see steady demand for diagnostic imaging storage and retrieval, especially in mid-sized facilities.
Cardiovascular Information System Market- Geographical Insights
North America leads the CVIS market, fueled by advanced healthcare infrastructure, widespread EHR integration, and government support for digital transformation. GE HealthCare's deployment of its Centricity Cardio Enterprise platform across Queensland's hospitals in Australia showcases success in the Asia Pacific, where markets such as India and China are rapidly adopting cloud-based CVIS to address large cardiac patient volumes. In Europe, the interoperability push and AI-enabled analytics are gaining traction in countries like Germany and the U.K.. Major strategic moves include Intelerad's acquisition of LUMEDX and Digisonics to build a stronger CVIS and imaging analytics platform, and Philips' acquisition of Cardiologs to enhance cloud-based ECG diagnostics and remote monitoring capabilities. These initiatives highlight region-wise growth, partnerships, and consolidation shaping this dynamic market.
The cardiovascular information systems market is shaped by consolidation and strategic acquisitions among leading players seeking to deliver integrated enterprise imaging and analytics. Intelerad Medical Systems acquired CVIS vendors Digisonics in December 2020 and Lumedx in early 2021, enhancing its capabilities in structured reporting, ECG management, and registries while serving over 650 hospitals globally. In mid-2021, Intelerad further expanded its cardiovascular imaging technology by acquiring HeartIT, boosting its clinical workflow and secure web-based visualization tools. Separately, Philips strengthened its cardiac diagnostics and remote monitoring portfolio by acquiring Cardiologs, integrating AI-based ECG analytics into its wider ecosystem that includes BioTelemetry and Capsule Technologies. These moves reflect the industry trend toward unified platforms offering CVIS, imaging, and cloud-enabled analytics for improved operational efficiency and patient outcomes.
In June 2024, Philips introduced its new Cardiac Workstation across Europe, the Middle East, and Africa, leveraging advanced algorithms to streamline ECG data collection, analysis, and interpretation at the point of care-enhancing workflow efficiency, clinical decision support, and enterprise interoperability.
In March 2025, GE HealthCare launched its first-of-its-kind unit-dose PET myocardial perfusion imaging agent, Flyrcado(TM) (flurpiridaz F-18), in select U.S. markets-granted CMS pass-through reimbursement-and showcased new AI-powered cardiology workflow innovations at ACC 2025.
In August 2024, GE HealthCare showcased its latest AI-enhanced cardiology solutions-including the CE-marked Vscan Air SL handheld ultrasound with Caption AI and ECG-less cardiac CT on the Revolution Apex platform-designed for real-time, point-of-care cardiac imaging and assessments.